Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748852 · ClinicalTrials.gov registry record · Phase 2
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
A Phase 2 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00748852 is a Phase 2 study that has completed, run by Akros Pharma. The registered enrollment target is 103 participants.
The verdict
NCT00748852, a Phase 2 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.
Interventions
- DRUG JTT-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748852
The ClinicalTrials.gov registry entry for NCT00748852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JTT-302 is the first listed.
NCT00748852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748852 about?
NCT00748852 is a clinical study titled "Safety Study of JTT-302 in Subjects With Low HDL-C Levels". The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.
What is the current status of trial NCT00748852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2007-01. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00748852?
The interventions under investigation include: JTT-302 (DRUG).
Who is sponsoring clinical trial NCT00748852?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.